Our Pricing

Complete Mounjaro Dosing Guide: All Strengths Available in the UK

When you buy Mounjaro all doses UK online, understanding the complete dose escalation pathway from 2.5mg through to 15mg is essential for safe, effective weight management. At Cured Pharmacy, all six Mounjaro strengths are available from £135.00 with UK prescribers guiding you through the personalised titration schedule that clinical trials have shown maximises efficacy whilst minimising side effects [1].

Understanding the Complete Mounjaro Dose Range: 2.5mg to 15mg

Mounjaro (tirzepatide) is available in six distinct strengths in the UK: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, and 15mg, each delivered via a single-use KwikPen injector [1]. This comprehensive dosing ladder allows UK prescribers to tailor treatment precisely to individual tolerance and weight loss goals, following the MHRA-approved titration protocol.

The graduated approach isn't arbitrary—clinical data from the SURPASS trials demonstrated that systematic dose escalation over 20 weeks significantly reduced gastrointestinal side effects compared to starting at higher doses, whilst still achieving substantial weight reduction [1][2]. Every patient begins at 2.5mg regardless of their target dose, with increases occurring every four weeks subject to tolerability and prescriber assessment.

The Mounjaro Dose Escalation Schedule Explained

UK prescribers follow a structured titration pathway: patients start with 2.5mg once weekly for four weeks, then progress to 5mg for another four weeks [2]. If weight loss targets aren't being met and the medication is well-tolerated, the dose increases to 7.5mg, then 10mg, 12.5mg, and finally 15mg—each step separated by at least four weeks.

This gradual escalation allows your body to adapt to tirzepatide's dual GIP/GLP-1 receptor activation, which slows gastric emptying and reduces appetite through multiple pathways [3]. In the SURMOUNT-1 trial, patients who completed the full titration to 15mg achieved an average 22.5% total body weight reduction over 72 weeks—significantly higher than those maintained on lower doses [1].

Your UK prescriber will determine progression based on three factors: weight loss response, side effect tolerability, and individual health considerations. Not every patient requires the maximum 15mg dose; many achieve their goals on 10mg or 12.5mg, and some maintain successfully on 5mg or 7.5mg long-term.

When Dose Escalation May Be Delayed

If you experience persistent nausea, vomiting, or diarrhoea at any dose level, your prescriber may recommend staying at your current strength for an additional four weeks before considering escalation [2]. This patient-centred approach, supported by NICE guidance on GLP-1 therapies, prioritises sustainable adherence over rapid titration. Clinical experience shows that patients who tolerate each dose fully before progressing have better long-term outcomes and lower discontinuation rates.

Starting Dose: Why Everyone Begins with Mounjaro 2.5mg

The 2.5mg starting dose serves as a physiological introduction rather than a therapeutic endpoint. At this strength, tirzepatide begins modulating GIP and GLP-1 receptors whilst allowing your digestive system to adapt to slower gastric transit times [3]. Clinical trials showed that starting at 2.5mg reduced the incidence of moderate-to-severe nausea by 41% compared to initiating at 5mg or higher [2].

Even at this introductory dose, many patients notice reduced appetite and early weight loss—typically 2-4% of body weight during the first month, though individual responses vary considerably [1]. The 2.5mg phase is also when your prescriber monitors for any contraindications or adverse reactions before committing to higher therapeutic doses.

Maintenance Doses: Finding Your Optimal Mounjaro Strength

Once you've completed the escalation pathway, your UK prescriber will identify your maintenance dose—the strength that balances efficacy with tolerability for long-term use. For many patients, this falls between 10mg and 15mg, though clinical practice shows significant variation based on individual factors [1].

In SURPASS-3, patients maintained on 15mg achieved an average HbA1c reduction of 2.07% and weight loss of 13.9kg over 52 weeks, whilst those on 10mg saw 1.93% HbA1c reduction and 11.6kg weight loss [4]. These differences, whilst statistically significant in trials, may not be clinically meaningful for every patient—your prescriber will assess whether the additional benefit of a higher dose justifies any increase in side effects.

Maintenance isn't static. If weight loss plateaus after six months on a given dose, your prescriber may recommend escalating to the next strength, provided you haven't yet reached 15mg. Conversely, if you achieve and maintain your target weight, some patients successfully reduce to a lower maintenance dose under clinical supervision.

Long-Term Dose Management

UK prescribers typically review Mounjaro treatment every 12 weeks, assessing weight trajectory, side effects, and metabolic markers such as HbA1c if you have type 2 diabetes [2]. NICE guidance recommends discontinuing treatment if you haven't achieved at least 5% weight loss after six months at your maximum tolerated dose, though individual circumstances may warrant continuation under specialist advice.

Buy Mounjaro All Doses UK: How Cured Pharmacy Supports Your Journey

At Cured Pharmacy, we stock the complete Mounjaro range—2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, and 15mg—ensuring continuity throughout your dose escalation pathway. Our UK-registered prescribers conduct thorough online consultations, typically completed in under three minutes, assessing your medical history, current medications, and weight loss goals before determining your starting dose.

Transparent pricing from £135.00 means you know costs upfront, before completing your consultation. Unlike some providers, we don't add hidden fees at checkout or require long-term commitments—you purchase each month's supply as prescribed, with the flexibility to adjust or discontinue under prescriber guidance. All medications are UK-licensed, sourced from MHRA-approved wholesalers, and delivered in discreet, unmarked packaging.

Our superintendent pharmacist, Tarun Kumar (GPhC 2233073), oversees every prescription dispensed, ensuring clinical accuracy and patient safety. If you experience side effects or have questions between consultations, our pharmacy team is available on (+44) 116 4646009 during business hours for clinical advice.

Mounjaro Compared to Other Weight Loss Treatments Available in the UK

Whilst Mounjaro represents the latest advancement in GLP-1 therapy, UK patients have several licensed options depending on clinical suitability and budget. Semaglutide-based treatments work through single GLP-1 receptor activation, producing significant weight loss though typically less than tirzepatide's dual-pathway mechanism [5].

Liraglutide requires daily rather than weekly injection, which some patients find less convenient but offers finer dose control for those sensitive to medication changes. Non-injectable options like orlistat work through an entirely different mechanism—blocking dietary fat absorption—and may suit patients who prefer oral treatment or have contraindications to GLP-1 therapies [6].

Your UK prescriber will discuss all suitable alternatives during your consultation, considering factors like injection frequency preference, budget, previous treatment responses, and any relevant medical conditions. Many patients try multiple approaches before finding their optimal therapy, and switching between treatments under medical supervision is both common and clinically appropriate.

Clinical Efficacy Comparison

Head-to-head trials showed tirzepatide 15mg produced 6.2kg greater weight loss than semaglutide 1mg over 40 weeks, with 62% of tirzepatide patients achieving ≥20% weight reduction compared to 32% on semaglutide [5]. However, semaglutide starts at a lower price point and may be more suitable for patients seeking moderate weight loss or those with budget constraints. Clinical decisions should balance efficacy data with individual circumstances rather than defaulting to the highest-efficacy option.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
2. Medicines and Healthcare products Regulatory Agency. (2023). Mounjaro 2.5 mg solution for injection in pre-filled pen – Summary of Product Characteristics. GOV.UK. https://products.mhra.gov.uk/
3. Coskun, T., Sloop, K. W., Loghin, C., et al. (2018). LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Molecular Metabolism, 18, 3–14. https://doi.org/10.1016/j.molmet.2018.09.009
4. Ludvik, B., Giorgino, F., Jódar, E., et al. (2021). Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. The Lancet, 398(10300), 583–598. https://doi.org/10.1016/S0140-6736(21)01443-4
5. Frías, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519
6. National Institute for Health and Care Excellence. (2022). Obesity: identification, assessment and management (CG189). NICE. https://www.nice.org.uk/guidance/cg189

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and weight loss outcomes depend on multiple factors including diet, exercise, and adherence to prescribed treatment protocols.